Intensity Therapeutics, Inc. (INTS), a Delaware-incorporated Emerging Growth Company trading on NASDAQ, secured immediate capital through a $4.0 Million Registered Direct Offering of Common Stock, detailed in an October 30, 2025 8-K filing.
The transaction involves the sale of 5,000,000 shares at a purchase price of $0.80 per share, expected to close on or about November 3, 2025, pursuant to an effective Form S-3 registration statement. The anticipated net proceeds are earmarked for advancing clinical trials and general working capital, providing an estimated cash runway until the end of Q1 2
...